ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Competitive Landscape of the New Drug Target Nectin-4 in China
May 22, 2023Araris Biotech AG announced on April 17 that it will acquire ARS Pharmaceutical's Nectin-4 antibody. Araris Biotech intends to use the acquired Nectin-4 antibody to develop differentiated Nectin-4 ADCs using its proprietary linker technology. -
A New Target in ADC: Nectin-4
September 14, 2021Recently, the application for clinical trail of Mabwell's ADC drug (9MW2821) targeting Nectin-4 has been accepted by NMPA. It is the first time that domestic enterprise enters the IND stage with the same target drug. -
Emergence Therapeutics Closes €87 Million Series A Financing Round
December 08, 2021Plans to advance its Nectin-4 antibody drug conjugate. -
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors
September 24, 2020Bicycle Therapeutics plc today announced the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT8009.
Pharma Sources Insight January 2025
